A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma

NCT05320692 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

423

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: TACE+Camrelizumab+Apatinib mesylate
PROCEDURE: TACE

Sponsor

Jiangsu HengRui Medicine Co., Ltd.